News Essex Bio-Technology Limited

Equities

1061

KYG312371035

Market Closed - Hong Kong S.E. Other stock markets 04:08:35 2024-04-19 am EDT			5-day change	1st Jan Change
2.31 ^HKD	0.00%		+5.00%	-7.23%

Mar. 18	Essex Bio-Technology Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 03	Essex Bio-Technology Limited Announces Change of Address of Head Office And principal Place of Business in Hong Kong	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover	Mar. 19	MT
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%	Mar. 18	AQ
Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024	Mar. 18	CI
Essex Bio-Technology Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Essex Bio-Technology Limited Announces Change of Address of Head Office And principal Place of Business in Hong Kong	Jan. 03	CI
Essex Bio-Technology Limited(SEHK:1061) dropped from S&P Global BMI Index	23-09-18	CI
Essex Bio-Technology's Profit Jumps 22% in H1	23-08-17	MT
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%	23-08-16	AQ
Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 13, 2023	23-08-16	CI
Essex Bio-Technology Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-16	CI
Essex Bio-Technology's Ophthalmic Injection Showed Safety, Efficacy in Trial	23-07-27	MT
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed	23-07-26	AQ
Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative Age-Related Macular Degeneration	23-07-26	CI
Essex Bio-Technology Limited Announces Early Repayment of Loan Facility	23-07-17	CI
Essex Bio-Technology Limited commences an Equity Buyback Plan for 57,064,900 shares, representing 10% of its issued share capital, under the authorization approved on June 9, 2023.	23-06-13	CI
Essex Bio-Technology Limited Announces Director Changes	23-06-09	CI
Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022	23-06-09	CI
Essex Bio-Technology Limited's Equity Buyback announced on May 12, 2022 has expired.	23-06-08	CI
Essex and Osteopore Entered into Exclusive Distribution Agreement	23-04-14	AQ
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore	23-04-14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Essex Bio-Technology Limited

Equities

1061

KYG312371035

Summary

Filters